Anterogen
안트로젠 · 065660
Industrials Trading & Distribution · KOSDAQ
Market cap US$186M (₩256.7B)
Overview
Anterogen is a South Korean biotech listed on KOSDAQ that develops and produces stem-cell-based therapies, treatments that use the body's own repair cells to address diseases that conventional medicine struggles to treat.
Its products are used by patients with conditions such as Crohn's disease-related fistulas and other rare or hard-to-treat illnesses. A key structural fact is that the company operates two distinct revenue streams: it develops and commercialises its own stem-cell therapies, and it also holds the domestic Korean distribution rights for two pulmonary arterial hypertension drugs, which it supplies exclusively in Korea.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$4.7M
- FY2024US$5M
- FY2025US$5.5M
Operating profit
- FY2023−US$3.7M
- FY2024−US$2.7M
- FY2025−US$1.8M
Net income
- FY2023−US$2.1M
- FY2024−US$1.7M
- FY2025−US$995.5K
Key ratios (FY2025)
Why it matters
Anterogen holds the Korean regulatory approval and exclusive domestic distribution rights for the pulmonary hypertension treatments Remodulin and Tyvaso, making it both a drug developer and a licensed distributor.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?